

## Contents

### Volume 21, 1987

Volume 21, Number 1

1987

#### CONTENTS

#### Special Issue: Adverse Events

- |   |    |   |
|---|----|---|
| <b>Allen Cato</b><br><b>Robert Temple</b>   | 1  | Foreword and Acknowledgments  |
| <b>Allen Cato</b>   | 3  | Premarketing Adverse Drug Experiences:<br>Data Management Procedures. Unexpected<br>Death Occurring Early in Clinical Trials          |
| <b>Robert T. O'Neill</b>  | 9  | Statistical Analyses of Adverse Event Data<br>from Clinical Trials. Special Emphasis<br>on Serious Events                             |
| <b>Karl E. Peace</b>  | 21 | Design, Monitoring, and Analysis Issues<br>Relative to Adverse Events   |
| <b>Michael Weintraub</b><br><b>Gerald Ginsberg</b>                                | 29 | Evaluating Liver Enzyme Abnormalities in<br>Clinical Trials Involving Diabetic Patients   |
| <b>Dorothy B. Windhorst</b><br><b>Edward F. C. Pun</b><br><b>Lonni A. Zubkoff</b> | 39 | Data on Drugs and Adverse Experiences:<br>Moving from the Specific to the General   |
| <b>Ursula Gundert-Remy</b>  | 47 | European View Toward Incorporating Adverse<br>Events into Package Inserts   |
| <b>Joel Morganroth</b>  | 51 | Remote Data Entry and the Electronic New Drug<br>Application: An Integrated Approach to Acquire,<br>Analyze, and Review New Drug Data |
| <b>Noel R. Mohberg</b>  | 55 | Some Observations on the Collection of Medical<br>Event Data  |
| <b>Judith Kramer LittleJohn</b>   | 63 | Package Insert: View of a Rural Town<br>Practitioner  |

*(Contents continued on next page)*

## A Primer on Postmarketing Surveillance

69 Editor's Note

71 Preface

*HISTORICAL PERSPECTIVE*

76 FDA Regulation of New Drugs

78 History of Postmarketing Surveillance in the United States

80 The Approach in Great Britain

83 Current Focus on Postmarketing Surveillance

83 Postmarketing Surveillance Activities of the FDA

83 Phase IV Studies

85 Summary of Industry Sponsored Phase IV Studies

*EXECUTIVE BRIEF*

93 Methods of Postmarketing Surveillance

95 Outline of Postmarketing Surveillance

99 Glossary of Postmarketing Surveillance Terms

*BIBLIOGRAPHY*

105 Pharmaco-Epidemiology Selected Bibliography

I Software Survey Section:

*PATH/TOX SYSTEM*

*RLAB PC LIMS*

*BALANCE*

*MODEL 2600 CHROMATOGRAPHY DATA*

*ACQUISITION*

*CAPTURE!*

*SIPHAR: INTEGRATED COMPUTER SYSTEM  
FOR PHARMACOKINETIC DATA ANALYSIS*

*SIGNWRITER (Instant Display Lettering)*

*PAPERBASE DELUXE*

*THE KEY*

*MEGASOURCE INVESTIGATIONAL DRUG  
TRACKING SYSTEM*

*MKMODEL*

## CONTENTS

- |                              |     |   |
|------------------------------|-----|---|
| <b>Stuart L. Nightingale</b> | 109 | Regulatory Overview: Protection of Human Subjects – IRBs and Informed Consent   |
| <b>Gurston Turner</b>        | 117 | FDA's Conduct, Review, and Evaluation of Inspections of Clinical Investigators  |
| <b>Alan B. Lisook</b>        |     |   |
| <b>Dana P. Delman</b>        |     |   |
| <b>Thomas J. Kirsch</b>      | 127 | The Interrelationships of Sponsors, Clinical Investigators, and Institutional Review Boards   |
| <b>Thomas H. Perez</b>       | 133 | Adverse Drug Reaction Reporting: Comparison of Reports Received by a Specialized Registry and the Food and Drug Administration System |
| <b>Joel N. Kuritsky</b>      |     |   |
| <b>Gerald A. Faich</b>       |     |   |
| <b>Robert S. Stern</b>       | 137 | Spontaneous Adverse Drug Reporting: Do Numbers Tell the Story?  |
| <b>Raymond H. Farman</b>     | 141 | Management of Pharmacokinetic Data Using HP-3357/Mainframe IBM Interfacing  |
| <b>Judi F. Muniak</b>        |     |   |
| <b>Kenneth A. Pittman</b>    |     |   |
| <b>Melvin P. Fisher</b>      | 153 | Preparation and Maintenance of Prescription Drug Labeling   |
| <b>Ann Summerfelt</b>        | 159 | Implementation of Clinical Trials: Simple, but Not Easy   |
| <b>Frank R. Funderburk</b>   |     |   |
| <b>G. Edward Collins</b>     | 165 | An Integrated Approach for Processing Information Inquiries at the Time of a New Product Launch                                       |
| <b>Cathy S. Frieden</b>      |     |   |
| <b>Gilles Cloutier</b>       |     |   |
| <b>Allen Cato</b>            |     |   |
| <b>Seymour Fisher</b>        | 173 | Detecting Adverse Drug Reactions in Postmarketing Surveillance: Interview Validity  |
| <b>Stephen G. Bryant</b>     |     |   |
| <b>Ronica M. Kluge</b>       |     |   |
| <b>Daniel E. Klingler</b>    | 185 | A Drug Safety Evaluation On-Line Study Log  |
| <b>Elizabeth H. Brown</b>    | 193 | Standard Operating Procedures for Computer Systems Validation   |
| <b>Leonard T. Sigell</b>     | 201 | The Role of Drug Information Centers with Consumers   |
| <b>J. Frank Bonfiglio</b>    |     |   |
| <b>Earl G. Siegel</b>        |     |   |
| <b>Edwin A. McCray</b>       |     |   |
| <b>Gaylene B. Tsipis</b>     |     |   |

- |  |     |   |
|--|-----|---|
| <b>Freya F. Hermann</b><br><b>Lee A. Wanke</b>             | 209 | Analysis and Control of Costs Associated<br>with Answering Drug Information Requests  |
| <b>Paula Botstein</b>                                      | 217 | Criteria for Approval of Controlled-Release<br>Products   |
| <b>Sanford A. Miller</b><br><b>Frank Edward Scarbrough</b> | 221 | Foods as Drugs  |
| <b>Ara Der Marderosian</b>                                 | 229 | Overview of the Use of Food/Natural Products as<br>Drugs  |
| <b>Norman R. Farnsworth</b>                                | 245 | International Perspectives Regarding the Use of<br>Food/Natural Products as Drugs   |
|  | I   | Software Survey Section<br><i>Sci-Mate Software System V2.0</i><br><i>Chromatography Software for</i><br><i>the HP-1000-A Series Computer</i><br><i>RLAB II</i><br><i>2600 Chromatography Software for the</i><br><i>IBM PC and Compatibles</i> |

## CONTENTS

- |  |     |  |
|--|-----|--|
| <b>Gerald A. Faich</b><br><b>Julie B. Milstien</b><br><b>Charles Anello</b><br><b>Carlene Baum</b> | 251 | Sources of Spontaneous Adverse Drug Reaction<br>Reports Received by Pharmaceutical Manufacturers |
| <b>Carlene Baum</b><br><b>Gerald A. Faich</b><br><b>Charles Anello</b><br><b>Mary B. Forbes</b>    | 257 | Differences in Manufacturer Reporting of<br>Adverse Drug Reactions to the FDA in 1984            |
| <b>Stefan H. Unger</b>   | 267 | Computer-Aided Drug Design in the Year 2000  |
| <b>Robert A. Michalak</b>  | 277 | Investigational Adverse Experience Reporting   |
| <b>Daniel E. Klingler</b>  | 283 | Documentation and Management of<br>Configurable Software   |

- C. A. Metz** 289 Development of a Training Program for  
**G. D. Gutknecht** New Clinical Research Personnel  
**J. C. Schneider**  
**A. Q. Sheridan**  
**C. J. Cross**  
**T. C. Vandermeulen**  
**K. P. Chapman**  
**J. P. Keelan**  
**W. Veldkamp**
- Erika F. Nissman** 295 The Use of COSTART at Burroughs  
 Wellcome Company
- Fred Schneiweiss** 299 Adverse Reaction Thesauri Used in the  
 Pharmaceutical Industry
- Fiona M. Cunningham** 303 QA Report Auditing: A Procedure for Selecting and  
**Kevin J. Gough** Identifying Data Points for Checking
- Nancy Mattison** 309 Postapproval Research Requested by the FDA at the  
**Barbara W. Richard** Time of NCE Approval, 1970-1984
- Bart Holland** 331 Monitoring Adverse Drug Reactions Using a  
**Steven Marcus** State Poison Control Center Data Base
- Alan M. Saltzman** 335 A MIS System for Worldwide Acquisition of Remote  
 Clinical Information
- G. James Davis** 353 The Successful Development Team: A Case Study  
**Daniel R. Klingler**
- Theresa E. Stokes** 361 Clinical Data Management and Remote Data Entry
- Frederick H. Fern** 367 Dual Regulatory Pharmaceutical Labeling Schemes:  
**Lewis Bartell** The Role of the Federal Preemption Doctrine
- I Software Survey Section:  
*CALS PEAKPRO*  
*CALS LAB MANAGER*

## CONTENTS

- Craig E. Hammes** 377 Foreword and Acknowledgements
- William E. Gilbertson** 379 FDA OTC Drug Standards Versus Cosmetic  
 Standards

<b>Heinz J. Eiermann</b>	387	Regulatory Requirements for Marketing Cosmetics in the United States
<b>Paul M. Hyman</b>	393	Regulatory Risks of Marketing Drugs and Cosmetics
<b>C. L. Hagenbush</b>	403	Practical and Theoretical Distinctions Between Drugs and Cosmetics
<b>Ann H. Wion</b>	409	Legal Perspective—OTC Drugs and Cosmetics
<b>Elizabeth B. D'Angelo</b>	417	Foreword and Acknowledgements
<b>William J. Meddick</b>	419	Computer Systems Validation: Dollars and Sense
<b>Daniel E. Klingler</b>	431	The Role of Rapid Prototypes in Software Validation
<b>Daniel Shirley</b>	441	Software Validation Strategies for Clinical Trials Systems
<b>Graham Martin J. Tony Wildsmith</b>	445	A New Approach to Error Reduction in the Acquisition and Delivery of Analytical Laboratory Data
<b>Thomas J. Ott Stephen A. Herczeg Robert K. Campbell</b>	455	Quality Assurance of Clinical Data in a Remote Data Entry Environment
<b>Will Anderson</b>	461	Software Validation Techniques
<b>D. C. Mattes B. J. Clark</b>	471	Development of Systematic Data Access and Integrity Features for Pharmaceutical Computer Applications
<b>Jay Herson</b>	475	Validation of Database Management System Applications for Clinical Trials
<b>Jonathan S. Kahan</b>	481	Legal Implications of Software Validation
<b>Maryanne Malone</b>	487	Managing the Validation Process
<b>J. C. Lynch M. A. Schreiber</b>	495	Documentation and Validation of a User Writer Program
<b>Michael Todd Roger Landau Theodore Koziol Robert Dwyer Kim Nitahara</b>	503	Validation of the Bioanalytical Computer Systems



517 Index to Volume 21, 1987

- I Software Survey Section:
  - ILEUM ver. 2.0*
  - CARDIOLAB*
  - Compudex*

